Dr. Cathy S. Cutler is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National Laboratory. Dr Cutler moved to the University of Missouri Research Reactor Centre's Radiopharmaceuticals Group in 1998. There she developed reactor processing methods for radioisotopes such as Lutetium-177 and developed targeting molecules such as nanoparticles for selective delivery. She worked there till June 2015. The MIRP group at Brookhaven operates the LINAC Isotope Producer (BLIP) that produces radioisotopes for commercial production as well as several research radioisotopes and is currently evaluating the accelerator production of Ac-225. Additionally, she directs the Radiopharmaceutical Research and Production Labs (RRPL) that processes targets from the BLIP. Dr Cutler's research focuses on developing production and separation methods for high specific activity theranostic radioisotopes, creating a suite of diagnostic and therapeutic agents tailored for individual needs which has been funded by the DOE, NIH, NSF and public foundations. She brings more than 28 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.